Head-to-Head

Arcutis Biotherapeutics, Inc. Common Stock vs. Eli Lilly & Co.

ARQT

Arcutis Biotherapeutics, Inc. Common Stock

$24.25 +1.53%

VS LLY

Eli Lilly & Co.

$1164.89 +1.04%

Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 9 compared factors.

Size & Scale

ARQTLLY
Market Cap $3.00 billion $1.03 trillion
Revenue (TTM) $463.98 million $79.67 billion
Net Income (TTM) $28.52 million $26.71 billion

LLY leads on 3 of 3 size & scale factors.

Valuation

ARQTLLY
P/E Ratio 115.48 39.10
Price / Book 13.61 30.33
Price / Sales 6.47 12.90

ARQT leads on 2 of 3 valuation factors.

Profitability

ARQTLLY
Net Margin 6.15% 33.53%
Return on Equity 12.93% 78.84%

LLY leads on 2 of 2 profitability factors.

Dividend

ARQTLLY
Dividend Yield — 0.59%
Payout Ratio — 23.23

ARQT and LLY split the dividend factors evenly.

Risk & Sentiment

ARQTLLY
Short Interest 0.19% 1.29%

ARQT leads on 1 of 1 risk & sentiment factors.

Dig deeper: ARQT overview, ARQT financials, LLY overview, LLY financials.

Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.